Onkologi
Highlights from ASCO 2021 The American Society of Clinical Oncology (ASCO) Annual Meeting was held virtually on 4-8 June.
We at BestPractice Nordic followed the meeting and met virtually with some of the leading oncologists to hear more about new studies and
interesting research results. You can read selected abstracts and watch short presentations on our platform bpno.no.
Below are some of the ASCO highlights.
NSCLC: Combination of nivolumab with chemotherapy for patients with NSCLC
Dr. Jonathan Spicer presents new analyses from the CheckMate-816 study, which show
that neoadjuvant nivolumab in combination
with platinum-doublet chemotherapy did not compromise tumor resection outcome and
significantly improved pathological complete response rate compared to chemothera-
py alone in patients with resectable non-small cell lung cancer.
Dr Spicer concludes that safety and surgical outcome, together with previously reported improvements in complete pathological
response, support nivolumab in combination with chemotherapy as an attractive neoad-
juvant treatment for patients with resectable NSCLC.
Jonathan Spicer, MD, PhD, FRCS, Associate Profes sor, Division of Thoracic Surgery Director, McGill Tho racic Oncology Network McGill University, Montreal General Hospital
BestPractice Nordic / NO / Onkologi og Hematologi / NR. 5 / 2021
9
